Virbac's Strategic Move to Enhance Feline Healthcare
Virbac is excited to announce its latest acquisition of an innovative treatment aimed at stabilizing feline hyperthyroidism. This acquisition highlights Virbac's commitment to improving the quality of life for older cats, especially as the segment of senior pets continues to grow.
Thyronorm: A Practical Solution for Hyperthyroidism
Under the Thyronorm brand, this new product will be directly distributed by Virbac in various regions, including Australia, the United Kingdom, and New Zealand. In the United States, it will be marketed under the Felanorm name. This acquisition aligns perfectly with Virbac's existing portfolio, allowing the company to expand its capabilities in veterinary medicine.
Understanding Feline Hyperthyroidism
Feline hyperthyroidism is an endocrine disorder impacting over 10% of older cats. This condition is characterized by the overproduction of thyroid hormones, leading to symptoms such as weight loss, irritability, and tachycardia. It’s a crucial health issue that demands timely diagnosis and management to prevent severe complications.
The Importance of Thyronorm
Thyronorm, which has been available since 2016, comes in a liquid formulation, making it easier for both veterinarians and pet owners to administer. This practical approach allows precise dosing and contributes to enhanced treatment efficacy, ultimately improving the daily lives of senior cats.
Future Collaborations and Potential
Virbac will maintain Norbrook as a trusted partner, who will continue to manufacture Thyronorm. The current revenue generated by this innovative product stands at approximately €14 million, with market sales nearing €27 million. This highlights the significant potential for growth and development in the feline healthcare market.
Building on Established Relationships
With its extensive global presence and strong connections in the veterinary field, Virbac is well-positioned to enhance the distribution and accessibility of Thyronorm. The company is dedicated to educating veterinarians and cat owners on the benefits of this product to ensure that more pets receive proper treatment.
Commitment to Animal Health
Virbac's commitment is exemplified by its CEO, Paul Martingell, who emphasizes the organization's dedication to advancing animal health. The acquisition of Thyronorm is just one step in Virbac's strategy to invest in innovative solutions that cater to unmet needs in veterinary care.
Supporting Senior Cats
By integrating Thyronorm into its portfolio, Virbac is prioritizing the needs of senior cats suffering from hyperthyroidism. The company aims to improve access to effective treatments through its extensive veterinary network, ultimately leading to healthier lives for these pets.
About Virbac
Virbac is dedicated to finding new ways to prevent, diagnose, and treat animal diseases. By developing a range of care, hygiene, and nutrition products, the company offers comprehensive solutions to veterinarians, farmers, and pet owners globally. Virbac’s mission is to advance the health of animals through collaboration with those who care for them daily.
Frequently Asked Questions
What is Virbac’s new acquisition about?
Virbac has acquired Thyronorm, an innovative treatment for feline hyperthyroidism aimed at improving the quality of life for senior cats.
How does Thyronorm benefit cats?
Thyronorm is a liquid medication that allows for easier administration and precise dosing to manage hyperthyroidism in cats effectively.
What is feline hyperthyroidism?
It is a common endocrine disease affecting older cats, characterized by excessive thyroid hormone production leading to various health issues.
Who will manufacture Thyronorm?
Norbrook will continue to manufacture Thyronorm while Virbac will oversee its distribution in select markets.
What is Virbac's mission?
Virbac aims to improve the health of animals by delivering innovative solutions and partnering with those who care for them.
